| Neurocrine Biosciences Inc. Q1 2010 Earnings Call Transcript Wyndham Worldwide Corporation (NBIX)Q1 2010 Earnings CallApril 29, 2010 8:30 a.m. ETComplete Story » seekingalpha.com |
Senate Acts to Block Doctors' Medicare Payment Cut Senate Democrats and Republicans agreed to postpone by six months scheduled cuts in Medicare payments to doctors. online.wsj.com |
Companies Give Back Q1 Gains - What Could Spark Q3? The Burrill Report submits: By Marie DaghlianFinancial markets whipsawed life sciences companies in the first half of 2010, driving up impressive gains during a robust first quarter, only to be pulled back to harsh reality during a turbulent second quarter. Complete Story » seekingalpha.com |
Boon for Biodefense The Burrill Report submits: By Michael Fitzhugh Two small California biotechs, Cellerant and Achaogen, have secured new multi-million dollar federal defense contracts to develop technologies for combating potential bioterrorism threats with clinical stage therapies.Complete Story » seekingalpha.com |
Bullish Trends at Keryx Biopharmaceuticals M.E. Garza submits: Shares of Keryx Biopharmaceuticals (Nasdaq: KERX) have started to trade higher and a Bullish flow has been detected in KERX with 6494 calls trading, or 5x the recent average daily call volume. Options traders are obviously placing their bets that this stock is headed higher.The emerging biopharma has two lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA and the stock price is rising ahead of the Phase 3 developments for Zerenex, which are due in December. Zerenex is an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Complete Story » seekingalpha.com |